National Institute of Drug Dependence, Peking University, Beijing, China.
Lancet. 2013 Oct 5;382(9899):1195-203. doi: 10.1016/S0140-6736(12)61898-4. Epub 2012 Dec 1.
On the basis of the results of the randomised clinical trial HPTN 052 and observational studies, WHO has recommended that antiretroviral therapy be offered to all HIV-infected individuals with uninfected partners of the opposite sex (serodiscordant couples) to reduce the risk of transmission. Whether or not such a public health approach is feasible and the outcomes are sustainable at a large scale and in a developing country setting has not previously been assessed.
In this retrospective observational cohort study, we included treated and treatment-naive HIV-positive individuals with HIV-negative partners of the opposite sex who had been added to the national HIV epidemiology and treatment databases between Jan 1, 2003 and Dec 31, 2011. We analysed the annual rate of HIV infection in HIV-negative partners during follow-up, stratified by treatment status of the index partner. Cox proportional hazards analyses were done to examine factors related to HIV transmission.
Based on data from 38,862 serodiscordant couples, with 101,295·1 person-years of follow-up for the seronegative partners, rates of HIV infection were 2·6 per 100 person-years (95% CI 2·4-2·8) among the 14,805 couples in the treatment-naive cohort (median baseline CD4 count for HIV-positive partners 441 cells per μl [IQR 314-590]) and 1·3 per 100 person-years (1·2-1·3) among the 24,057 couples in the treated cohort (median baseline CD4 count for HIV-positive partners 168 cells per μl [62-269]). We calculated a 26% relative reduction in HIV transmission (adjusted hazard ratio 0·74, 95% CI 0·65-0·84) in the treated cohort. The reduction in transmission was seen across almost all demographic subgroups and was significant in the first year (0·64, 0·54-0·76), and among couples in which the HIV-positive partner had been infected by blood or plasma transfusion (0·76, 0·59-0·99) or heterosexual intercourse (0·69, 0·56-0·84), but not among couples in which the HIV-positive partner was infected by injecting drugs (0·98, 0·71-1·36).
Antiretroviral therapy for HIV-positive individuals in serodiscordant couples reduced HIV transmission across China, which suggests that the treatment-as-prevention approach is a feasible public health prevention strategy on a national scale in a developing country context. The durability and generalisability of such protection, however, needs to be further studied.
Chinese Government's 12th Five-Year Plan, the National Natural Science Foundation of China, and the Canadian International Development Research Centre.
基于随机临床试验 HPTN 052 和观察性研究的结果,世界卫生组织建议向所有与异性无感染伴侣(血清不一致的夫妇)感染 HIV 的个体提供抗逆转录病毒治疗,以降低传播风险。这种公共卫生方法是否可行,以及在大规模和发展中国家环境中是否可持续,以前尚未得到评估。
在这项回顾性观察性队列研究中,我们纳入了 2003 年 1 月 1 日至 2011 年 12 月 31 日期间纳入国家艾滋病毒流行病学和治疗数据库的接受治疗和未经治疗的 HIV 阳性个体,以及他们 HIV 阴性的异性伴侣。我们分析了在随访期间 HIV 阴性伴侣的 HIV 感染年发生率,按指数伴侣的治疗状况分层。我们使用 Cox 比例风险分析来研究与 HIV 传播相关的因素。
基于来自 38862 对血清不一致的夫妇的数据,其中 HIV 阴性伴侣的随访时间为 101295.1 人年,在未经治疗的队列中,14805 对夫妇的 HIV 感染率为每 100 人年 2.6 例(95%CI 2.4-2.8)(HIV 阳性伴侣的中位基线 CD4 计数为 441 个细胞/μl [314-590]),在接受治疗的队列中,24057 对夫妇的 HIV 感染率为每 100 人年 1.3 例(1.2-1.3)(HIV 阳性伴侣的中位基线 CD4 计数为 168 个细胞/μl [62-269])。我们计算出治疗队列中 HIV 传播的相对减少了 26%(调整后的危险比 0.74,95%CI 0.65-0.84)。这种传播的减少在几乎所有的人口统计学亚组中都有看到,在第一年最为显著(0.64,0.54-0.76),在 HIV 阳性伴侣通过血液或血浆输注感染的夫妇中(0.76,0.59-0.99)或异性性行为(0.69,0.56-0.84),但在 HIV 阳性伴侣通过注射吸毒感染的夫妇中没有(0.98,0.71-1.36)。
在中国,针对血清不一致的夫妇中 HIV 阳性个体的抗逆转录病毒治疗降低了 HIV 传播,这表明治疗即预防的方法是在发展中国家背景下,在全国范围内实施可行的公共卫生预防策略。然而,这种保护的持久性和普遍性需要进一步研究。
中国政府的第十二个五年计划、国家自然科学基金和加拿大国际发展研究中心。